Coming together for immuno-oncology
Takeda Pharmaceutical Company Limited and MIT’s Koch Institute for Integrative Cancer Research recently announced that Takeda will support groundbreaking science in immuno-oncology at the Koch Institute (KI). The $1 million gift will help, over the next two years, to both build upon research currently being conducted at the KI on the role of the immune response in cancer, and to develop potential novel treatments. The gift will also allow investigators to test their most innovative new ideas and collaborations, conducting early-stage seed projects that can have a major impact but are difficult to fund. “The Koch Institute was created to promote the best in science and engineering to develop new approaches in the fight against cancer,” said Tyler Jacks, director of the Koch Institute. “Immuno-oncology is a major focus of our efforts, and we are grateful to Takeda for their support in this important area of research.” Investigators at the Koch Institute are...